Moneycontrol PRO
HomeNewsBusinessMoneycontrol Pro Panorama | Climbing up the value ladder

Moneycontrol Pro Panorama | Climbing up the value ladder

For December 10 edition of Moneycontrol Pro Panorama: Shaktikanta Das — RBI governor for all seasons, a reduction in CRR may not be enough, testing times for the securitisation market, Emmanuel Macron weathers the storm to take France forward, and more

December 10, 2024 / 15:05 IST
Businesses get commoditised over a period of time.

Dear Reader,

The Panorama newsletter is sent to Moneycontrol Pro subscribers on market days. It offers easy access to stories published on Moneycontrol Pro and gives a little extra by setting out a context or an event or trend that investors should keep track of.

Businesses get commoditised over a period of time. When that happens, companies can protect and grow their businesses by climbing the value chain, by adding new product categories or strengthening existing ones. The latest acquisitions made by Metropolis Healthcare and CEAT are examples of how this thought process can play out.

Metropolis is acquiring oncology-focused diagnostic services provider Core Diagnostics. Earlier, CEAT has said it has entered into an agreement to acquire off-highway construction equipment bias tyre and tracks business from Michelin.

Metropolis and CEAT are in the same business as the target companies. Metropolis offers cancer tests and CEAT sells off-highway tyres.

Even so, Core Diagnostics will expand Metropolis’s presence in high end oncology tests and in the northern and eastern parts of the country. As Abdulkader Puranwala, analyst at ICICI Securities, explains, the general diagnostics business is increasingly coming under pressure from new entrants — hospitals, pharmacies and online based service providers. Amid growing competition, one option for diagnostic service providers to strengthen their business is by deepening their presence in specialised tests. The share of oncology revenue in Metropolis's total sales will grow from 4 percent to 10 percent, post the acquisition of Core Diagnostics.

Similarly, the acquisition of Camso brand’s business from Michelin will give impetus to CEAT’s off-highway tyre business. The Camso brand has a strong presence in original equipment and replacement tyre markets in North America and the European Union. The business potential in the off-highway tyres has been well demonstrated by Balkrishna Industries over the past 10 years.

The acquisition will expand CEAT’s revenues by 15 percent. Notably, the acquisition helps CEAT expand its relatively high profit margin off-highway tyres business, crucial in the current context of heightened volatility in raw material prices. “CEAT’s acquisition comes at a time when most tyre firms are striving to foray into making niche speciality tyres. They are moving towards improving brand equity and higher premiumisation in the product mix,” writes Vatsala Kamat. Do Read.

Of course, acquisitions are rarely without risks. Dr Lal PathLabs faced hiccups in integrating and scaling up Suburban Diagnostics. Oncology based specialised tests are doctor prescription driven. Ensuring close relations with doctors and hospitals continue under a changed management is vital for Metropolis. For CEAT, the Camso acquisition comes with two manufacturing plants in Sri Lanka and customers in several countries across the globe. A smooth transition is vital to derive the acquisition's benefits and ultimately translate into gains for investors of the acquiring companies, too.

Investing insights from our research team

Yes Bank – Why a no till a deal materialises

Should one avoid the FMCG sector now?

Discovery Series: Bikaji Foods International -- A tasty treat

MapmyIndia: Will the stock rerate after the apparent victory of minority shareholders?

Tracker

Pro Economic Tracker: Auto sales, labour participation decline; consumer sentiment improves

What else are we reading?

Shaktikanta Das era ends at Mint Road — RBI governor for all seasons

Why the 50 bps CRR cut may not move the needle

A booming securitisation market would be put to the test soon

Chart of the Day: India's contract pharma research market to outpace global growth

Can the US monetise Bitcoin as a currency?

Wall Street’s complex debt bonanza hits fastest pace since 2007 (republished from the FT)
Shaktikanta Das: A left-field Governor’s rollercoaster tenure

Syria: Liberation or perdition?

Crypto doesn’t deserve a tax exemption

French President Emmanuel Macron takes a step back, to go two steps forward

What would Asia look like without US leadership?

Markets

Golden era for Indian capital markets; over a dozen stocks to ride the wave, says Motilal Oswal report

Tech and Startups

Shift to fixed-price deals, Gen AI challenges IT offshore models

Technical Picks: LUPIN.

R Sree Ram
Moneycontrol Pro  

R. Sree Ram
first published: Dec 10, 2024 03:02 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347
CloseOutskill Genai